HomeComparePFLT vs PKI

PFLT vs PKI: Dividend Comparison 2026

PFLT yields 15.85% · PKI yields 0.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFLT wins by $58.7K in total portfolio value
10 years
PFLT
PFLT
● Live price
15.85%
Share price
$7.76
Annual div
$1.23
5Y div CAGR
5.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.4K
Annual income
$9,644.04
Full PFLT calculator →
PKI
PKI
● Live price
0.24%
Share price
$115.24
Annual div
$0.28
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.02
Full PKI calculator →

Portfolio growth — PFLT vs PKI

📍 PFLT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFLTPKI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFLT + PKI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFLT pays
PKI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFLT
Annual income on $10K today (after 15% tax)
$1,347.29/yr
After 10yr DRIP, annual income (after tax)
$8,197.43/yr
PKI
Annual income on $10K today (after 15% tax)
$20.65/yr
After 10yr DRIP, annual income (after tax)
$0.02/yr
At 15% tax rate, PFLT beats the other by $8,197.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFLT + PKI for your $10,000?

PFLT: 50%PKI: 50%
100% PKI50/50100% PFLT
Portfolio after 10yr
$49.1K
Annual income
$4,822.03/yr
Blended yield
9.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PKI right now

PFLT
Analyst Ratings
5
Buy
5
Hold
Consensus: Buy
Price Target
$10.00
+28.9% upside vs current
Range: $9.50 — $10.50
Altman Z
0.3
Piotroski
4/9
PKI
Analyst Ratings
13
Buy
18
Hold
Consensus: Hold
Price Target
$166.57
+44.5% upside vs current
Range: $145.00 — $202.00
Altman Z
2.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFLT buys
0
PKI buys
0
No recent congressional trades found for PFLT or PKI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFLTPKI
Forward yield15.85%0.24%
Annual dividend / share$1.23$0.28
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.7%-50%
Portfolio after 10y$78.4K$19.7K
Annual income after 10y$9,644.04$0.02
Total dividends collected$47.2K$24.00
Payment frequencyquarterlyquarterly
SectorBDCStock
Analyst consensusBuyHold
Analyst price target$10.00$166.57

Year-by-year: PFLT vs PKI ($10,000, DRIP)

YearPFLT PortfolioPFLT Income/yrPKI PortfolioPKI Income/yrGap
1← crossover$12,375$1,675.40$10,712$12.15+$1.7KPFLT
2$15,290$2,048.18$11,468$6.08+$3.8KPFLT
3$18,860$2,499.79$12,274$3.04+$6.6KPFLT
4$23,226$3,046.02$13,135$1.52+$10.1KPFLT
5$28,558$3,705.62$14,055$0.76+$14.5KPFLT
6$35,058$4,500.87$15,039$0.38+$20.0KPFLT
7$42,970$5,458.17$16,092$0.19+$26.9KPFLT
8$52,586$6,608.75$17,218$0.10+$35.4KPFLT
9$64,257$7,989.52$18,424$0.05+$45.8KPFLT
10$78,399$9,644.04$19,713$0.02+$58.7KPFLT

PFLT vs PKI: Complete Analysis 2026

PFLTBDC

PennantPark Floating Rate Capital Ltd. is a business development company. It seeks to make secondary direct, debt, equity, and loan investments. The fund seeks to invest through floating rate loans in private or thinly traded or small market-cap, public middle market companies. It primarily invests in the United States and to a limited extent non-U.S. companies. The fund typically invests between $2 million and $20 million. The fund also invests in equity securities, such as preferred stock, common stock, warrants or options received in connection with debt investments or through direct investments. It primarily invests between $10 million and $50 million in investments in senior secured loans and mezzanine debt. It seeks to invest in companies not rated by national rating agencies. The companies if rated would be between BB and CCC under the Standard & Poor's system. The fund invests 30% is invested in non-qualifying assets like investments in public companies whose securities are not thinly traded or do not have a market capitalization of less than $250 million, securities of middle-market companies located outside of the United States, high-yield bonds, distressed debt, private equity, securities of public companies that are not thinly traded, and investment companies as defined in the 1940 Act. Under normal conditions, the fund expects atleast 80 percent of its net assets plus any borrowings for investment purposes to be invested in Floating Rate Loans and investments with similar economic characteristics, including cash equivalents invested in money market funds. It expects to represent 65 percent of its portfolio through senior secured loans. In case of floating rate loans, it holds investments for a period of three to ten years.

Full PFLT Calculator →

PKIStock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Full PKI Calculator →
📬

Get this PFLT vs PKI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFLT vs SCHDPFLT vs JEPIPFLT vs OPFLT vs KOPFLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.